Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 258-649-2 | CAS number: 53585-53-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 02 August 1989 to 13 December 1989
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 992
- Report date:
- 1992
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- Study conducted prior to the adoption of the most recent version of this guideline.
- Deviations:
- yes
- Remarks:
- The animals were treated for at least 120 days instead of 90; the neurobiological examination was not performed; it is not reported whether opthalmoscopic examination was conducted before the beginning of the treatment period.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Dibenzylbenzene, ar-methyl derivative
- EC Number:
- 258-649-2
- EC Name:
- Dibenzylbenzene, ar-methyl derivative
- Cas Number:
- 53585-53-8
- Molecular formula:
- C21H20
- IUPAC Name:
- dibenzylbenzene, ar-methyl derivative
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, France
- Age at study initiation: approximately 7 weeks old
- Weight at study initiation:
Mean initial bodyweight for males was 185 g
Mean initial bodyweight for females was 160 g
- Diet (e.g. ad libitum): a complete commercial diet ad libitum
- Water (e.g. ad libitum): tap-water through automatic waterers ad libitum
- Acclimation period: at least 1 week before beginning treatment
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2
- Humidity (%): 60 +/- 10
- Air changes (per hr): 12
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 02 August To: 13 December 1989
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 10% gum arabic solution
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The compound was prepared extemporaneously as a suspension in a 10% aqueous gum arabic solution
VEHICLE
- Justification for use and choice of vehicle (if other than water): no
- Concentration in vehicle: 10 %
- Amount of vehicle (if gavage): 5 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analyses were carried out during the study to control the concentration of suspensions at approximately 3 months, 4 months and 4 months and 2 weeks after the beginning of the treatment period.
- Duration of treatment / exposure:
- At least 120 days (between 133 and 142)
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 5 mg/kg bw/day (nominal)
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- post-exposure period : no
- Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: No data
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: The animals were observed at least twice daily (at least once on Saturdays, Sundays and public holidays) throughout the study for clinical signs (for which date of onset and progression were recorded) and for mortality.
BODY WEIGHT: Yes
- Time schedule for examinations: animals were weighed before the beginning of the treatment period, then weekly throughout the study.
FOOD CONSUMPTION : Yes
- Time schedule: individual food intake was measured weekly from which mean individual daily values were calculated on a weekly basis.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: day 126
- Dose groups that were examined: all animals
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on days 128 and 129
- Anaesthetic used for blood collection: No
- Animals fasted: Yes
- How many animals: 80
- Parameters checked in table [1] were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: days 132 and 133
- Animals fasted: Yes
- How many animals: 80
- Parameters checked in table [2] were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: days 121 to 125
- Metabolism cages used for collection of urine: No data
- Animals fasted: No
- How many animals: 40
- Parameters checked in table [3] were examined.
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- Necropsy was performed from day 134 to day 143.
GROSS PATHOLOGY: Yes (see table 4 for tissues examined and table 5 for organ weights )
HISTOPATHOLOGY: Yes (see table 6) - Other examinations:
- Not reported; no treatment-free period performed.
- Statistics:
- 1. Parametric methods
Parametric, statistical tests are used when the theoretical distribution of the data is normal.
Step 1 consists of the Levene test for the equality of variances.
. If the Levene test cannot be performed or is not significant (equal variances), step 2 consists of testing for a treatment (group) effect using one-way analysis of variance (1-ANOVA).
- If 1-ANOVA is not significant, no further analysis is performed, the means being considered not different.
- If 1-ANOVA is significant (rejection of null hypothesis that population means are equal), step 3 consists of intergroup comparisons by the Student t test taking 1-ANOVA residual variance as a pooled estimate of the variability.
. If the Levene test is significant (unequal variances), step 2 consists of pairwise comparisons of variances (with the reference group) using the Snedecor F statistic.
- If a pairwise comparison is not significant (equal variances), step 3 consists of intergroup comparison by the classical Student t test.
- If a pairwise comparison is significant (unequal variances), step 3 consists of intergroup comparisons by the approximate Student t test using Welch's method.
To take into account multiple comparisons, p values are calculated according to Bonferroni's method (<= 6 comparisons) or Scheffé's method (> 6 comparisons).
2. Non-parametric methods
Non-parametric methods are routinely used when the theoretical distribution of the data is not normal.
Overall equality of the group means is tested by the Kruskall Wallis test. If the test is significant (unequal means), then intergroup comparisons are carried out pairwise by the same method. If the test is not significant, the means are considered to be not different.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Soiled urogenital area, blood on the muzzle and thinness were noted in one female given 50 mg/kg bw/day from day 100. Soiled urogenital area or blood on the muzzle was also noted, respectively, in one female or one male given 5 mg/kg bw/day. Hair loss was noted in one female given 50 mg/kg bw/day. These signs were not considered as related to the treatment with the compound.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One male given 5 mg/kg bw/day and one male given 500 mg/kg bw/day were found dead on days 61 and 60, respectively. Death was attributed to probable inhalation pneumonia following oesophageal occlusion as shown by the microscopic examination.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No treatment-related variations were noted in the body weight gain.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- A slight increase (sometimes statistically significant compared to controls) was noted in the animals given 500 mg/kg bw/day throughout the study.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related lesions were observed at the end of the treatment period.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There were no relevant variations that can be related to the treatment with the test substance.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- An increase in total cholesterol level (+69% compared to the controls) was noted in males given 500 mg/kg bw/day. A slight decrease in creatininemia was noted in the test substance-treated groups without dose relationship. This change has no toxicological significance.
- Endocrine findings:
- not examined
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- An increase in the absolute and relative kidney weight (approximately + 20%) was noted in the males given 500 mg/kg/day. As this was not associated with histological or biological modifications, this increase was considered to be of no toxicological significance.
A slight increase in the relative liver weight (with increase absolute values which however, were not statistically significant) was noted in the males and females given 500 mg/kg bw/day. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- The post-mortem examinations performed on all animals did no show any treatment-related lesions
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- A slight hypertrophy of centrilobular hepatocytes was noted in 2/10 males given 50 mg/kg/day and 10/10 males given 500 mg/kg bw/day. In 4/10 males of the high dose group, this was accompanied with a slight hypertrophy of the mediolobular hepatocytes. These changes were more or less associated with a decrease in the incidence of hepatocytes cytoplasmiques margination.
Histopathology of the decedent animals:
Moderate or marked acute pulmonary edema (congestion and alveolar edema) was seen in the two decedent animals, with perivascular edema and intra-alveolar hemorrhage in animal given 5 mg/kg bw/day and serosity in laryngeal and tracheal lumen in animal given 500 mg/kg/bw/day.
Moderate and marked distension of the oesophageal lumen by vegetal particles was noted and found also, mixed with serosity, in the tracheal and pharyngeal lumen in animal given 5 mg/kg bw/day.
Slight vacuolation of centrilobular hepatocytes was seen in animal given 5 mg/kg bw/day as well as moderate adrenocortical hyperplasia and various congestion changes in animal given 500 mg/kg/day. These changes are of little significance. - Histopathological findings: neoplastic:
- not examined
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- Dose descriptor:
- LOAEL
- Effect level:
- 500 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical biochemistry
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- System:
- hepatobiliary
- Organ:
- liver
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
Any other information on results incl. tables
Table 7 Clinical chemistry - relevant/statistical changes
Exposure Group |
Control |
5 mg/kg/d |
50 mg/kg/d |
500 mg/kg/d |
Males |
||||
Clinical Chemistry |
||||
Total cholesterol nM |
1.67 +/- 0.076 |
1.95 +/- 0.163 |
2.07 +/- 0.102 |
2.82 +/- 0.130* |
* Statistically significant difference from the control group
Applicant's summary and conclusion
- Conclusions:
- In this 4-month oral toxicity study, the NOAEL was found to be 50 mg/kg bw/day, based on a LOAEL estimated at 500 mg/kg bw/day (effects on liver in both sexes).
When dibenzyltoluene (trade name: JARYLEC DBT) is administered at 50 mg/kg bw/day, slight hypertrophy of centrilobular hepatocytes was seen in few animals (2/20) without any other changes. Thus, this dose level was considered as the NOAEL. - Executive summary:
The aim of the present study was to assess the oral toxicity of dibenzytoluene (trade name: JARYLEC DBT) to Sprague Dawley rats. The compound was administered once a day by gavage for at least 120 days at the dose levels of 0, 5, 50 and 500 mg/kg bw/day. Each group was composed of 10 males and 10 females. The control group received the vehicle only (l0 % gum arabic solution). The clinical signs were observed twice a day, the body-weight and the food consumption were recorded once a week. For all animals, ophthalmology, clinical pathology, hematology investigations and urine analysis were performed after at least 120 days of treatment. After at least 120 days of treatment, the rats were sacrificed and a full macroscopic examination was performed, selected organs weighted, and certain organs submitted to histological examination.
No treatment-related mortality or clinical signs were noted and the growth rate of animals was unmodified. Ophthalmoscopic and hematological examinations, urinalysis and macroscopic examinations did not show any treatment-related lesions. At 500 mg/kg bw/day, the compound induced changes suggesting an enzyme induction: hypertrophy of centrilobular (and sometimes mediolobular) hepatocytes in most animals associated with a slight increase in cholesterol levels in males, a slight increase in food intake and in the relative liver weight in both sexes. A slight increase in kidney weight was noted in high-dose males, but it was considered without toxicological relevance since it was not associated with histological or biological modifications. At 50 mg/kg bw/day, only two males showed a slight hypertrophy of centrilobular hepatocytes without any other changes; Thus, this dose level was considered as a non-toxic dose. Consequently, under the experimental conditions of this 4-month oral toxicity study, the NOAEL was found to be 50 mg/kg bw/day, based on a LOAEL estimated at 500 mg/kg bw/day (effects on liver in both sexes).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.